INTRODUCTION
Worldwide, colorectal cancer (CRC) is the third most common cancer diagnosed in men and the second most common cancer diagnosed in women. 1 In developed countries, the incidence of CRC is higher and mortality is lower than in less developed countries. 1 In the United States, colon cancer comprises approximately two-thirds of incident CRCs and is the third most commonly diagnosed cancer among men and women. 2 There were nearly 42,000 deaths from colon cancer in 2013, representing nearly 81% of CRC deaths. 2 The incidence of colon cancer has been decreasing steadily since 2001; most recently, incidence declined an average of 3% per year between 2005 and 2014. 3 Mortality from colon and rectal cancers also has been declining for the past several decades, with the most rapid declines in the early 2000s, likely because of screening. 3, 4 Despite these overall reductions, colon cancer incidence and mortality remain substantially higher among blacks than among other races/ethnicities and are higher among men than among women. 2 Population-based cancer survival provides an indicator of the overall effectiveness of the health care system to deliver screening, early diagnosis, and evidenced-based treatment services to all individuals in the population being served. 5 The first worldwide analysis of cancer survival (CONCORD), which was conducted in 31 countries among patients who were diagnosed between 1990 and 1994 and were followed until 1999, covered 42% of the US population. 6 In the United
States, 5-year survival for colon cancer was 60.1%, with lower survival among blacks (51%) than whites (61%). 6 These differences may have resulted from black patients not having received the same standard of care, including access to screening, early diagnosis, and optimal treatment, as that received by white patients. 6 Subsequent analysis of cancer survival worldwide (CONCORD-2) in 67 countries compared patients who were diagnosed with 1 of 10 common cancers, including colon cancer, between 1995 and 2009 and were followed until 2009 or later. Five-year net survival for colon cancer was 60% or greater in North America, 12 European countries, and a few countries in Central and South America and Asia. 7 For the United States, 5-year net survival for colon cancer increased from 61% for patients who were diagnosed between 1995 and 1999 to 65% in those diagnosed between 2005 and 2009. 7 For the current study, we used data from CONCORD-2 to provide the first detailed assessment of survival for colon cancer 
MATERIALS AND METHODS

Data Source
We used data from 37 population-based state cancer registries funded by either the Centers for Disease Control and Prevention's (CDC's) National Program of Cancer Registries, or the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program, or both. 8 These registries participated in the CONCORD-2 study, 7 which covered approximately 80% of the United States population, and consented to the inclusion of their data in the more detailed analyses reported here. This analysis included 813,103 males and females (ages 15-99 years) who were diagnosed with invasive colon cancer between 2001 and 2009 with follow-up through December 31, 2009. As defined in the original study, for colon cancer, we included both the colon and the rectosigmoid junction (International Classification of Diseases for Oncology, third edition; codes C18.0-C18.9 and C19.9). 7 Primary invasive cancers were included regardless of whether the patient had a previous cancer. If the patient was diagnosed with 2 or more cancers of the colon between 2001 and 2009, then only the first cancer was considered in the survival analyses.
Patients were grouped by year of diagnosis into 2 calendar periods (2001-2003 and 2004-2009) 
Statistical Analysis
Net survival at 1 year, 3 years, and 5 years, with 95% confidence intervals (CIs), was estimated for patients who were diagnosed between 2001 and 2003 or between 2004 and 2009 by state, race, and stage at diagnosis using the Pohar Perme estimator, which allows for an unbiased estimation of net survival, ie, the probability that patients will survive their cancer up to a given time since diagnosis, after controlling for other causes of death (background mortality). 11 To control for wide differences in background mortality among participating states, life tables of all-cause mortality in the general population of each state were constructed from the number of deaths and the population by single year of age, sex, calendar year, and, where possible, by race (black, white), using a flexible Poisson model. 12 Methods for constructing life tables have been published. 13 For patients who were diagnosed between 2001 and 2003, the cohort approach was used to estimate net survival, because all patients had been followed for at least 5 years by December 31, 2009. The complete approach was used to estimate 5-year net survival for patients who were diagnosed between 2004 and 2009, because 5 years of follow-up data were not available for all patients. Net survival was estimated for 5 age groups (ages 15-44, 45-54, 55-64, 65-74, and 75-99 years). All estimates were agestandardized using the International Cancer Survival Standard (ICSS) weights.
14 If 2 or more of the 5 agespecific estimates could not be obtained, then unstandardized survival estimates for all ages combined are presented. The overall results for colon cancer are presented; however, state-specific results are reported in Supporting Tables 1, 2 and 3. All unstandardized estimates are italicized in Supporting Tables 2 and 3 . Trends, geographic variations, and differences in age-standardized survival by race are presented graphically in bar charts and funnel plots. 15 Funnel plots of net survival for the 2 calendar periods provide a simple and informative display of geographic variations or trends in population-based cancer survival measures (eg, age-standardized net survival) in the United States, by race and state. Specifically, the plots illustrate how much a particular survival estimate deviates from the pooled estimate of US registries (the target represented in the plot by the horizontal line) given the precision of each estimate. 15 More details on the data and methods are provided in an accompanying article by Allemani et al. 16 19 .3%, respectively), and there was a decrease in the proportion diagnosed at regional stage (from 39.3% to 34.9%) ( Table 1 ). The percentage of patients with unknown stage decreased from 8.9% to 7.9%. Among blacks, the proportion of patients diagnosed at a localized stage increased from 29.1% to 33.8%, the proportion diagnosed at a regional stage decreased from 37.4% to 32.7%, and the proportion diagnosed at a distant stage increased from 21.5% to 23.3%. Among whites, the proportion of patients diagnosed at a localized stage increased from 34.8% to 38.4%, the proportion diagnosed at a regional stage decreased from 39.5% to 35.2%, and the proportion diagnosed at a distant stage increased from 17.2% to 18.8%. Between the 2 calendar periods, the absolute difference in the proportion of black patients and white patients diagnosed at a localized stage fell slightly (from 5.7% to 4.6% higher among white patients than black patients) and was essentially unchanged for those diagnosed at a regional stage (from 2.1% to 2.5% higher among white patients than black patients) and at distant stages (from 4.3% to 4.5% lower among white patients than black patients). In nearly all states, the proportion of black patients diagnosed with localized stage was lower than that for white patients in both calendar periods (Supporting Table 1 Table 2 ).
RESULTS
Five-year net survival for colon cancer was highest for patients who were diagnosed at a localized stage, followed by regional stage, and then distant stage (Table 3) . There was no change in 5-year net survival between the 2 calendar periods for patients who were diagnosed at a localized stage, but survival increased for those diagnosed at a regional stage (from 68.7% to 70.2%) and at distant stages (from 11.1% to 13.8%).
Blacks experienced poorer 5-year net survival than whites at all stages and in both periods of diagnosis; however, the absolute difference in survival between blacks and whites decreased slightly between the 2 calendar periods for localized stage (from 6.7% to 4.9%) and remained essentially unchanged for regional and distant stages. Survival up to 5 years after diagnosis was lower among blacks Table 3 ). Figure 1 illustrates 5-year net survival for the US (pooled estimate), which increased by 1.0%, and for each participating state. Survival ranged from 59.8% to 69.5% between 2001 and 2003 and from 60.9% to 69.7% between 2004 and 2009 across the 37 participating states (Supporting Table 3 ). The largest increase in survival was 5.0%, whereas the largest decrease in survival was 26.6%.
Funnel plots of net survival for the 2 calendar periods (2001-2003 and 2004-2009 ) demonstrate striking geographic and racial variations in survival (Fig. 2) . Although 5-year survival from colon cancer increased slightly between 2001 to 2003 and 2004 to 2009 in most states, it was lower for blacks (range, 50%-60%) than for whites (range, 60%-70%) in nearly every state for which data were available. Between 2004 and 2009, there was a slight shift upward in survival and some overlap, whereby the highest survival for blacks was similar to the lowest survival for whites. In all 26 states for which a survival estimate could be obtained for blacks, survival was systematically lower than the pooled estimate for all 37 US registries combined.
DISCUSSION
This population-based study is the largest to date demonstrating trends in survival up to 5 years after diagnosis for colon cancer by stage, race, and US state. There was a modest increase in 5-year colon cancer survival between the periods 2001 to 2003 and 2004 to 2009 for patients diagnosed at regional or distant stages, but not for patients with locally staged cancer, for whom survival was already high (90%). Survival was not equal between states or by race. Five-year survival varied considerably among states but improved in most states between the 2 calendar periods. Five-year net survival was much lower among black patients than among white patients at all stages of disease, and this racial disparity decreased by only 1% over the decade.
Changes in survival likely reflect changes in screening, stage at diagnosis, and treatment. 17 The small increases in 1-year, 3-year, and 5-year colon cancer survival between the 2 calendar periods may reflect gains in survival achieved in the first calendar period. Since 1998, Medicare has covered annual fecal occult blood test and sigmoidoscopy every 4 years for average-risk beneficiaries aged 50 years and older. In July 2001, coverage was expanded to include colonoscopy for average-risk individuals every 10 years. Consequently, there was a rapid increase in the use of colonoscopy and an increased probability of diagnosis at an early stage among older adults. 18 Since 2000, screening has increased for individuals aged 50 to 75 years, and colonoscopy has become the most commonly used test; however, the use of screening tests among blacks has remained lower than that among whites. 19 In the current study, there was an increase in earlier stage at diagnosis for both black and white patients. However, a larger proportion of blacks than whites were diagnosed at later stages of disease, which may be partially explained by the historically lower screening rates among blacks compared with whites. 20, 21 Finally, the uneven distribution of access to high-quality treatment may explain the minimal improvement in survival.
Populations that reside in low socioeconomic and/or rural areas are less likely to receive high-quality treatment for colon cancer than their counterparts.
22
The wide variation in survival observed between states may reflect differences in access to screening and high-quality treatment. States that have greater proportions of rural and lower socioeconomic status (SES) populations tend to fare worse in colon cancer outcomes.
23
Populations with low SES, including the uninsured, are less likely to be up to date for CRC screening according to recommendations. In 2015, the lowest CRC screening use was reported by individuals who were uninsured (25.1%). 19 Access to and receipt of high-quality treatment are subject to geographic variation. Residents of rural and/ or low-SES neighborhoods have more limited access to hospitals that offer high-quality treatment than residents of urban areas or high-SES neighborhoods. One study indicated that patients who received treatment in hospitals without a Commission on Cancer designation or with lower surgical volumes had lower odds of an adequate lymph node assessment, 24 a key factor in staging and treatment. Another study indicated that patients with colon cancer residing in low-SES and lower/middle-SES neighborhoods had decreased odds of receiving surgery and chemotherapy than patients residing in high-SES neighborhoods.
22 Those investigators also observed that rural residents had an increased risk of death from colon cancer that was explained by treatment differences and neighborhood SES.
22
Five-year survival improved modestly between the 2 calendar periods for patients who were diagnosed with regional and distant-stage colon cancers. Advances in treatment have improved survival for those diagnosed with later stage disease. [25] [26] [27] In the late 1980s, 5-fluorouracil-based adjuvant chemotherapy for patients with surgically resectable stage III colon cancer was introduced. 28, 29 In clinical trials, this treatment reduced mortality from colon cancer by as much as 30%. Later, the 1990 National Institutes of Health expert panel recommended that patients with stage III colon cancer receive adjuvant therapy with 5-fluorouracil-based chemotherapy and levamisole. In the first CONCORD study, cancer survival among blacks diagnosed between 1990 and 1994 was 51.5% in men and 51.0% in women, while survival in whites was 60.5% and 60.8%, respectively. 6 Survival among black patients diagnosed between 2004 and 2009 was 54.5% in men and 58.6% in women compared with 64.5% and 66.4%, respectively among whites. 16 The disparities observed may reflect differences in access to screening and receipt of high quality health care. 17, 31, 32 Factors that have been shown to be associated with racial disparities in survival include differences in SES, 33 Blacks had lower stage-specific 5-year survival than whites. The decrease in the magnitude of the disparities between the 2 calendar periods, although small, was seen at every stage. Several studies have noted that black patients with CRC are less likely than white patients to receive appropriate surgery, adjuvant chemotherapy, and radiation treatments. 33, 35 In settings where black and white patients with similarly staged disease receive comparable cancer treatment, survival differences by race are reduced.
37
Clinical Perspective
To further reduce colon cancer incidence and mortality and improve survival, increased efforts are needed to ensure that individuals are offered screening at the appropriate age, undergo timely diagnostic follow-up, receive high-quality treatment, and have adequate post-treatment surveillance. For colon cancers diagnosed at invasive stages, the wide differences in net survival between blacks and whites, and by state, reflect both the uneven use of effective treatment and the distribution of factors that affect recommendation and uptake of treatment (eg, SES, health literacy, health care access, insurance coverage, physician recommendation, and patient factors, such as health beliefs, culture, and comorbidities). Additional investigation may be needed to assess adherence to standards of treatment for colon cancer and to develop effective interventions to improve recommendation of and adherence to high-quality treatment.
Recent research has demonstrated that primary tumor location may play a role in survival for colon cancer. Patients whose primary tumors originate on the left side of the colon survive significantly longer than those whose tumors originate on the right side.
38 Right-sided colon cancers are more likely to be poorly differentiated tumors and to be diagnosed at a more advanced stage, and both of these factors are associated with poor survival. 39 Additional research is needed to gain a better understanding of the tumor biology behind these differences in survival and to determine whether there is a need to change the approach to colon cancer treatment by managing it according to tumor location. Ultimately, a better understanding of the differences in tumor biology may also affect the choice of treatment modalities, specifically, the chemotherapy regimens used for right-sided versus left-sided colon cancer.
Cancer-Control Perspective
Efforts of the CDC to reduce the burden of colon cancer in the United States have largely focused on CRC screening, awareness, and education. The CDC's Colorectal Cancer Control Program funds states, universities, and tribal organizations to partner with health care systems and implement evidence-based interventions to increase the use of CRC screening tests for adults ages 50 to 75 years. 8, 40 In some states, the program also provides screening and follow-up for positive tests in adults ages 50 to 64 years who are uninsured or underinsured and below 250% of the Federal Poverty Level. 40 In addition to the Colorectal Cancer Control Program, the National Comprehensive Cancer Control Program brings together key partners and organizations to develop and implement plans to address the cancer burden. 8, 41 Finally, the CDC and its partners are leading a national initiative to increase CRC screening rates to 80% by 2018. 42 By achieving this goal, it is estimated that approximately 280,000 new cancer cases and 200,000 cancer deaths will be averted within 20 years. 42 To help achieve this screening goal, public health professionals could partner with health care systems to help design processes that ensure patients receive quality care along the entire continuum of care, from screening, to diagnosis, to treatment, and survivorship, including the provision of culturally and linguistically appropriate services or implementation of the National CLAS (Culturally and Linguistically Appropriate Services) standards. 43 Cancer screening registries can be used to improve followup of patients who have positive screening tests and to implement evidence-based interventions, such as reminder systems. 44 Furthermore, to address the disparities observed in the current study, more research is needed to explore the geographic distribution of screening and treatment services and factors contributing to the use or nonuse of these services, within and between states, and what can be done to improve access in low-access areas and in medically underserved populations.
Strengths and Limitations
The CONCORD-2 study is the largest comparative study of population-based survival in the United States and includes high-quality data that cover 80% of the US population. The overall quality of the CONCORD-2 data, the rigorous statistical methods used, and the large population coverage are such that the results presented provide a broad and comprehensive overview of trends and racial disparities in survival among patients diagnosed with cancer in the United States. Details on the strengths and limitations of these data are described elsewhere. 45 For colon cancer, there was a high percentage of microscopically confirmed colon cancers (97.6%), with no differences by race, indicating a high degree of clinical investigation of patients in the United States. 16 Furthermore, considering the populationbased nature of this study, the proportion of patients who had colon cancer with unknown stage was remarkably low However, the completeness of stage information is remarkably high, and the differences in the proportion of unknown stage by race are not large. We would not expect these differences to affect the comparison of stage-specific survival by race.
Our findings are subject to some limitations. 45 First, caution should be used in comparing these results with other published studies using US data. In the CONCORD-2 data, cancers that occur in the sigmoidrectum junction are classified as colon cancer. In the United States, this site is typically classified as cancer of the rectum. Second, there were several state estimates that fell outside the control limits, as illustrated in the funnel plots. For estimates that were above the control limits (ie, survival was higher than expected), caution should be used in interpreting the results, because these registries may have not captured all patients, particularly those who leave the United States between the time of their diagnosis and death.
Conclusions
The United States has made some progress in improving survival for patients diagnosed with colon cancer, particularly for those who were diagnosed at a regional or distant stage. However, progress was not uniform across all states or by race. Five-year survival among blacks who were diagnosed between 2004 and 2009 still had not reached the level of survival among whites who were diagnosed between 1990 and 1994, some 15 to 20 years earlier.
More work is needed to reduce the wide disparities observed by state and race, and targeted interventions are needed to reach the most vulnerable populations. Trends in population-based cancer survival can be used to inform policy and can serve as benchmarks for states to measure the impact of their cancer-control programs. 
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